The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-02. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
=== HLX === Following the release of Half-Life: Alyx in 2020, dataminers examining updates to the Source 2 engine discovered that Valve was developing a non-VR game codenamed HLX. On December 31, 2024, Mike Shapiro, the voice actor for the G-Man, posted a cryptic message on X suggesting "unexpected surprises" in the new year. In April, it was reported that HLX was being playtested and would be a sequel to Episode Two. Industry insiders, dataminers and leakers reported that Valve was planning a 2025 announcement for HLX. In December, the Insider Gaming senior editor Mike Straw said HLX was planned as a launch game for Valve's Steam Machine hardware, and the announcement had been delayed by the rising cost of RAM.
The amylin receptors (AMYRs) are a family of 3 receptors that are activated by amylin, a peptide hormone secreted together with insulin. They are each composed of a copy of the calcitonin receptor (CTR) bound to a receptor activity-modifying protein (RAMP), forming a heterodimer. They consist of AMY1 (RAMP1 with CTR), AMY2 (RAMP2 with CTR), and AMY3 (RAMP3 with CTR). Activation of these receptors appears to have a number of effects on eating behavior, including triggering feelings of satiation, reducing food intake, decreasing fat storage, and increasing energy usage. These effects have led to research into targeting these receptors with treatments for metabolic diseases and obesity. The amylin receptors are G protein-coupled receptor of the secretin receptor family. Consistent with their calcitonin receptor subunit, they appear to activate Gs alpha subunit pathways, and there have also been reports of Gq alpha subunit coupling. However, methodological difficulties related to amylin’s ability to bind with the calcitonin receptor have led some researchers to express uncertainty about these results.
== External links == Official website Example SWAPO Party Youth League web page. "Latest from the SPYL Frontlines". spyl.swapo.party. SWAPO Party Youth League. 28 August 2012. Archived from the original on 28 August 2012. Retrieved 7 November 2024.
== Homology == Several organisms possess multiple CPA2 paralogues. Thus, E. coli has three, Methanococcus jannaschii has four and Synechocystis sp. has five paralogues. The potassium efflux system, Kef, protects bacteria against the detrimental effects of electrophilic compounds via acidification of the cytoplasm. Kef is inhibited by glutathione (GSH) but activated by glutathione-S-conjugates (GS-X) formed in the presence of electrophiles. GSH and GS-X bind to overlapping sites on Kef, which are located in a cytosolic regulatory domain.
Sources: en.wikipedia.org
Co-precipitation is a facile and convenient way to synthesize iron oxides (either Fe3O4 or γ-Fe2O3) from aqueous Fe2+/Fe3+ salt solutions by the addition of a base under inert atmosphere at room temperature or at elevated temperature. The size, shape, and composition of the magnetic nanoparticles very much depends on the type of salts used (e.g.chlorides, sulfates, nitrates), the Fe2+/Fe3+ ratio, the reaction temperature, the pH value and ionic strength of the media, and the mixing rate with the base solution used to provoke the precipitation. The co-precipitation approach has been used extensively to produce ferrite nanoparticles of controlled sizes and magnetic properties. A variety of experimental arrangements have been reported to facilitate continuous and large–scale co–precipitation of magnetic particles by rapid mixing. Recently, the growth rate of the magnetic nanoparticles was measured in real-time during the precipitation of magnetite nanoparticles by an integrated AC magnetic susceptometer within the mixing zone of the reactants.
=== Smoking === Smoking tobacco has been shown to increase caffeine clearance by 56% as a result of polycyclic aromatic hydrocarbons inducing the CYP1A2 enzyme. The CYP1A2 enzyme that is induced by smoking is responsible for the metabolism of caffeine; increased enzyme activity leads to increased caffeine clearance, and is associated with greater coffee consumption for regular smokers.
Escitalopram was developed in cooperation between Lundbeck and Forest Laboratories. Its development was initiated in 1997, and the resulting new drug application was submitted to the US FDA in March 2001. The short time (3.5 years) it took to develop escitalopram can be attributed to the previous experience of Lundbeck and Forest with citalopram, which has similar pharmacology.
== Early years == Rodrigo Roa Duterte was born on March 28, 1945, in Maasin, Leyte. His father was Vicente Gonzales Duterte (1911–1968), a Cebuano lawyer, and his mother, Soledad Gonzales Roa (1916–2012), was a schoolteacher from Cabadbaran, Agusan and a civic leader, of Chinese and Spanish mestizo descent. Duterte has said that his grandfather was Chinese and hailed from Xiamen in Fujian, China. Duterte has four siblings: Eleanor (born 1941/42), Emmanuel, Jocelyn (1948–2023) and Benjamin ("Bong", 1953–2026). Duterte's father was mayor of Danao, Cebu, and subsequently the provincial governor of (the then-undivided) Davao province. Rodrigo's cousin Ronald was mayor of Cebu City from 1983 to 1986. Ronald's father, Ramon Duterte, also held that position from 1957 to 1959. The Dutertes consider the Cebu-based political families of the Durano and the Almendras clan as relatives. Duterte also has relatives from the Roa clan in Leyte through his mother's side. Duterte's family lived in Maasin, and in his father's hometown in Danao, until he was four years old. Duterte was heavily influenced by his mother, who unlike Vicente was a staunch anti-Marcos activist, which led the young Duterte to have a divided opinion on the Marcoses. Duterte later said Marcos could have been the best president, but he was a dictator. The Dutertes initially moved to Mindanao in 1948 but still went back and forth to the Visayas until 1949. They finally settled in the Davao Region in 1950. Vicente worked as a lawyer engaged in private practice.
In 2016, DeepMind's WaveNet demonstrated that deep neural networks can generate raw audio waveforms. This enabled more realistic speech synthesis compared to earlier approaches. Subsequent systems such as Tacotron 2 demonstrated end-to-end neural text-to-speech generation.
Sources: en.wikipedia.org
The Weimaraner is of medium to large size: dogs stand some 59 to 70 cm at the withers, bitches about 57 to 65 cm; weights are in the range 30–40 kg for dogs, 25–35 kg for bitches. The coat may be either short or long; a double coat of intermediate length is sometimes seen. The coat may be mouse-grey, roe-grey or silver-grey in various shades, or of a colour intermediate between these; minor white markings to the feet and chest are tolerated. The eyes are amber, ranging from pale to dark; the ears are pendent, with rounded tips. Among the neurological diseases associated with the Weimaraner are cerebellar hypoplasia, hypomyelinogenesis and spinal dysraphism. Other diseases or defects to which it has some genetic or statistical predisposition include corneal dystrophy, distichiasis, entropion, eversion of the cartilage of the nictitating membrane, generalised demodicosis, medial canthal pocket syndrome, refractory corneal ulceration and XX sex reversal, and also – in dogs only – Weimaraner neutrophil dysfunction, pododermatitis and tricuspid dysplasia. A 2024 UK study found a median lifespan of 12.8 years for the breed compared to an average of 12.7 for purebreeds and 12 for crossbreeds.
=== Cholesterol clearance === Synthetic platelets are being explored for their potential in cholesterol clearance by facilitating the targeted removal of cholesterol from the bloodstream, offering a novel approach to treating hypercholesterolemia and preventing cardiovascular diseases. Elevated low-density lipoprotein cholesterol (LDL-C) is a key contributor to coronary heart disease, largely regulated by the interaction between LDL receptors (LDLR) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Since PCSK9 reduces LDLR availability, inhibiting it can enhance LDL-C clearance. To explore this, researchers designed platelet-mimicking nanoparticles to deliver siRNA targeting Pcsk9. These nanoparticles effectively lowered Pcsk9 mRNA levels by 66% in cell studies and reduced plasma LDL-C by 28% in animal models, without significantly altering high-density lipoprotein cholesterol (HDL-C) or triglycerides (TGs). This strategy demonstrates the potential of biomimetic nanoparticles for RNA-based therapies aimed at treating high cholesterol.
Lad's father, Shivaji, died when Santosh was 16 years old. He is married to Keerthi Lad; they have a son, Karan Lad. His 2023 election affidavit identifies him as a businessman/entrepreneur and identifies his spouse's occupation as homemaker.
Eddy stayed there for two years, from 1868 to 1870, teaching Wentworth with Quimby's unpublished essay, "Questions and Answers." She acknowledged that the manuscript was Quimby's, and spoke often of how she had promised to teach his healing method, which at the time she called Moral Science.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.